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Urology (TLJT), Tampere University Hospital and UKK Institute for Health Promotion Research (JR), Tampere, FinlandPurpose: Screening for prostate cancer remains controversial, although ERSPC
(European Randomized Study of Screening for Prostate Cancer) showed a 21%
relative reduction in prostate cancer mortality. The Finnish Randomized Study
of Screening for Prostate Cancer, which is the largest component of ERSPC,
demonstrated a statistically nonsignificant 16% mortality benefit in a separate
analysis. The purpose of this study was to estimate the degree of contamination
in the control arm of the Finnish trial.
Materials and Methods: Altogether 48,295 and 31,872 men were randomized to
the control and screening arms, respectively. The screening period was 1996 to
2007. The extent of prostate specific antigen testing was analyzed retrospectively
using laboratory databases. The incidence of T1c prostate cancer (impalpable
prostate cancer detected by elevated prostate specific antigen) was determined
from the national Finnish Cancer Registry.
Results: Approximately 1.4% of men had undergone prostate specific antigen
testing 1 to 3 years before randomization. By the first 4, 8 and 12 years of fol-
lowup 18.1%, 47.7% and 62.7% of men in the control arm had undergone prostate
specific antigen testing at least once and in the screening arm the proportions
were 69.8%, 81.1% and 85.2%, respectively. The cumulative incidence of T1c
prostate cancer was 6.1% in the screening arm and 4.5% in the control arm (RR
1.21, 95% CI 1.13e1.30).
Conclusions: A large proportion of men in the control arm had undergone a
prostate specific antigen test during the 15-year followup. Contamination is
likely to dilute differences in prostate cancer mortality between the arms in the
Finnish screening trial.
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mass screening, biasPOPULATION based screening for PCa
remains controversial despite the sub-
stantial 21%decrease inPCamortality
observed in ERSPC at 13 years of fol-
lowup.1 This beneficialmortality effect
is counterbalanced by substantial over22-5347/17/1981-0050/0
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cally insignificant PCa.1,2 Also, quality
of life effects and cost-effectiveness
require further elucidation.3,4
The ERSPC trial involves 8 centers
with some differences in the protocolH, INC.
http://dx.doi.org/10.1016/j.juro.2017.01.048
Vol. 198, 50-57, July 2017
Printed in U.S.A.
ESTIMATE OF OPPORTUNISTIC PROSTATE SPECIFIC ANTIGEN TESTING 51in relation to PSA threshold, interval and recruit-
ment method.1 To our knowledge it is currently the
only randomized trial that has shown a mortality
benefit from population based screening.5 The 3
largest centers of the ERSPC trial have reported
mortality results separately. The Swedish center
with 20,000 men who were 50 to 64 years old at
randomization reported a substantial reduction in
PCa mortality at 14 years (HR 0.56, 95% CI
0.39e0.82).6 The Finnish center with 80,000 men
who were 55 to 67 years old reported a modest,
statistically nonsignificant reduction (HR 0.85, 95%
CI 0.69e1.04).7 Finally, the Dutch center with
35,000 men with a core age of 55 to 69 years
reported a significant result (RR 0.68, 95% CI
0.53e0.89).8
Another large, randomized PCa screening trial,
the PLCO trial in the United States, demonstrated a
risk ratio of 1.09 (95% CI 0.87e1.36) for PCa mor-
tality at 13 years of followup.9 A major shortcoming
in the PLCO trial is the substantial frequency of
PSA testing before randomization, which was done
in 44% of men in both arms and during followup in
the control arm with 40% to 52% of controls
screened each year.10,11 A recent report showed that
in fact as many as 90% of men in the CA underwent
PSA testing before or during the trial.12
Contamination in a randomized trial means that
nonorganized (ie opportunistic) intervention in the
CA dilutes the observed effect of the intervention
because the comparator is not the absence of
screening but rather less common and less system-
atic screening. In other words as some men in the
CA receive opportunistic PSA testing, the contrast
in the procedures received is reduced and, thus, the
relative difference (eg in mortality) is decreased.
The purpose of the current study was to estimate
the frequency of contamination at the Finnish cen-
ter using regional laboratory databases and the
incidence of T1c PCa (impalpable cancer detected by
abnormal PSA) as an indicator of the outcome of
PSA testing to determine effective contamination.MATERIALS AND METHODS
The Finnish Randomized Study of Screening for Prostate
Cancer is the largest center of the ERSPC trial (http://
www.isrctn.com/ISRCTN49127736). Men were identified
from the population registry in 1996 to 1999. Each year a
random sample of 8,000 men in the Helsinki or Tampere
metropolitan area were randomized to the SA. The rest of
the age group formed the CA. Men were 55 to 67 years old
at study entry. Those in the CA were not contacted.
Men in the SA were invited to undergo serum PSA
determination at a local clinic. They were re-invited 4 and
8 years later to subsequent PSA tests. Those men 71 years
old or older were no longer invited. Men with a serum PSA
4.0 ng/ml or greater were referred for diagnosticevaluation, ie transrectal prostate biopsies. Men with PSA
3.0 to 3.99 ng/ml were referred for an additional test, ie
digital rectal examination in 1996 to 1998 and the free-to-
total PSA ratio with a cutoff of less than 16% in 1999 and
thereafter. Men with an abnormal result were referred for
biopsy. Those who had died or emigrated from the study
area or Finland were identified from the population
registry.
Information on all PCas were obtained from the
Finnish Cancer Registry, which has 99% coverage of solid
cancers.13 Information on opportunistic PSA testing was
retrospectively extracted from regional laboratory data-
bases, including HUSLAB in Helsinki, and TamLab and
Fimlab in Tampere. These databases have essentially
complete coverage on tests administered in public health
care, including primary health care, and central and
university hospitals. Tests at private clinics were not
available for this study. For reference in Finland in 2012
approximately 25% of primary health care contacts were
provided by the private sector.14
In the SA the data on organized screens were appended
to the opportunistic testing. Information on the intent of
PSA testing was not available, ie whether the patient was
symptomatic or asymptomatic at the time of the test.
Laboratory data from Helsinki covered a study period
from January 1996 to July 2012 and data from Tampere
covered January 1996 to December 2010. Followup
regarding PSA testing ended at 1) the first PSA test
(overall PSA testing analyses), 2) the first positive PSA
test (positive PSA test analyses), 3) PCa diagnosis,
4) emigration, 5) death or 6) the common study closing
date of July 31, 2012 in Helsinki and December 31, 2010
in Tampere, whichever was first. Data on the PCa inci-
dence in all men were available through December 2014.
For screening and contamination tests a positive test
wasdefinedas total serumPSA4.0ng/ml or greater, or total
serum PSA 3.0 to 3.99 and a free-to-total PSA ratio of less
than 16%. The total number of PSA tests per person was
recorded. Information onPSA testing before randomization
was available on men randomized in 1997 (1 previous
yeard1996), in 1998 (2 previous yearsd1996 and 1997)
and in 1999 (3 previous yearsd1996 through 1998).
Incidence rate ratios of the first PSA test, the first
positive PSA test and the T1c PCa diagnosis were esti-
mated using Poisson regression with person-years as the
offset. Center (Helsinki or Tampere) and age at event
served as covariates. The Kaplan-Meier failure estimates
method was utilized to graphically present the cumulative
incidence. STATA, version 14 was used for all analyses,
95% CIs are shown and all statistical tests were 2-sided.
The study protocol was reviewed by the Helsinki
and Tampere University Hospital Ethics committees.
Permission to use cancer registry and laboratory data was
obtained from STAKES (Research and Development
Centre for Welfare and Health), currently named the
National Institute for Health and Welfare.RESULTS
There were 31,872 men in the SA and 48,295 in the
CA (fig. 1). Median followup was 15.6 years in both
Figure 1. Finnish Randomized Study of Screening for Prostate Cancer flow chart
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maximum of 18.6 years. Median time to the
first PSA test in all men was 0.8 years in the SA and
6.9 years in the CA. Median followup in those
not tested was 11.8 and 14.0 years in the SA and
the CA, respectively. Median age at the first PSA
test was 61.3 years in the SA and 66.1 years in
the CA.
Prior to randomization 0.7% of men in both arms
had undergone a PSA test, ie they were pre-
screened. Of men with the longest pretrial followup
of 3 years before randomization in 1999, 1.7% (137
of 7,957) were prescreened in the SA and 2.1% (258
of 12,441) were prescreened in the CA. By 4 years
after randomization 18.1% of men in the CA had
been tested at least once (table 1). By 8 years of
followup the cumulative incidence of PSA testing
was 47.7% in the CA and by 12 years it had reached
62.7%. During the active screening period of 1996 to
2007 in the SA 28,073 men (58.1%) in the CA had
been tested at least once. By the end of followup
32,860 men (68.0%) in the CA had been tested
(fig. 2).Men in the CA underwent a mean of 2.9 PSA
tests (median 2.0, IQR 0e4). In the SA a mean of 4.3
PSA tests per person were done (median 3.0,
IQR 1e6).
Of men in the CA 10,691 (22.1%) tested positive
at least once whereas in the SA 8,172 (25.6%) tested
positive (table 1 and fig. 3). The RR of the incidence
of a positive PSA test in the SA vs the CA was 1.20
(95% CI 1.16e1.23).
When analyzed by calendar year, during the first
4 years of the trial (1996 to 1999) only 7.8% of men
in the CA underwent opportunistic testing during
the first screening round. However, nonorganized
PSA testing became common during the second
screening round (2000 to 2003). During this period
37.1% of men in the CA were tested at least once. In
the third round (2004 to 2007) more than half of the
men in the CA underwent PSA testing (table 2).
Each year the proportion of positive PSA tests of
all tests was clearly higher in the CA than in the SA.
However, after organized screening ceased in 2008,
the proportion of positive tests was similar in the 2
arms (table 2).
Table 1. Incidence of PSA testing, positive tests, T1c cancers
by screening interval and followup since randomization
Incidence No. Pts








1996e1999 31,872 26,732 (83.9) 1,284 (4.8‡) 297 (0.9)
2000e2003 30,062 24,941 (83.0) 3,751 (15.0‡) 557 (1.9)
2004e2007 27,130 21,016 (77.5) 5,178 (24.6‡) 690 (2.5)
Cumulative followup (yrs):
Less than 4 31,872 22,242 (69.8) 2,475 (7.8†) 383 (1.2)
4eLess than 8 e 25,858 (81.1) 5,078 (15.9†) 1,001 (3.1)
8eLess than 12 e 27,155 (85.2) 7,224 (22.7†) 1,651 (5.2)
12 or Greater e 27,554 (86.4) 8,172 (25.6†) 1,948 (6.1)
Control arm
Per screening interval:
1996e1999 48,295 3,779 (7.8) 913 (24.2‡) 120 (0.3)
2000e2003 46,173 17,122 (37.1) 4,904 (28.6‡) 427 (0.9)
2004e2007 42,161 21,935 (52.0) 8,652 (39.4‡) 769 (1.8)
Cumulative followup (yrs):
Less than 4 48,295 8,749 (18.1) 1,793 (3.7†) 262 (0.5)
4eLess than 8 e 23,051 (47.7) 5,494 (11.4†) 856 (1.8)
8eLess than 12 e 30,265 (62.7) 8,843 (18.3†) 1,560 (3.2)
12 or Greater e 32,860 (68.0) 10,691 (22.1†) 2,180 (4.5)
*Total serum PSA 4.0 ng/ml or greater, or 3.0 to 3.99 ng/ml and free-to-total PSA
ratio less than 16%.
†Divided by number of tests.
‡Divided by number of patients.
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9.7%) were detected in the CA and 3,589 were found
in the SA (11.3%, RR 1.12, 95% CI 1.07e1.18). Of all
PCas 2,180 (4.5%) and 1,946 (6.1%) were classifiedFigure 2. Incidence of PSA testing ias T1c in the CA and the SA, respectively (T1c
incidence RR 1.21, 95% CI 1.13e1.30, fig. 4).DISCUSSION
Our findings demonstrate considerable frequency of
nonorganized PSA testing (ie contamination) in the
CA of the Finnish Randomized Study of Screening
for Prostate Cancer. However, pretrial PSA testing
was rare in both arms at 1.4%. Contamination
remained at a moderate level in the first 4 years of
the trial since fewer than 20% of men in the CA
were tested compared to 70% in the SA. Median
time to the first PSA test was 0.8 years in the SA vs
6.9 years in the CA. However, 50% of men in the CA
had been tested at least once by year 8. This is also
reflected in the high 4.5% cumulative incidence of
T1c cancers (impalpable cancers detected by
abnormal PSA) in the CA, although the T1c inci-
dence was 1.2-fold in the SA.
The effect of screening can be diminished if the
trial population is screened prior to baseline as the
risk of disease and mortality from it is lower in a
previously screened population. In the PLCO trial
the prevalence of prerandomization PSA testing
was estimated to be as high as 45% in both arms.10
The Swedish branch of ERSPC reported that
approximately 3% of men had been tested for PSAn control and screening arms
Figure 3. Incidence of positive PSA test in control and screening arms
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mated that approximately 13% of men had been
screened with PSA before trial entry.15 Our results
show that fewer than 2% of men in the Finnish trial
had been prescreened. However, the true proportion
is likely to be higher because we only had informa-
tion on the previous 1 to 3 years before screening.




No. at Least 1
PSA Test (%)
No. Pos
Test (%)* No. T1c (%)
1996 7,960 5,955 (74.8) 85 (1.4) 28 (0.35)
1997 15,761 7,550 (47.9) 313 (4.1) 74 (0.47)
1998 23,347 7,266 (31.1) 383 (5.3) 87 (0.37)
1999 30,766 7,873 (25.6) 503 (6.4) 108 (0.35)
2000 30,065 7,602 (25.3) 736 (9.7) 118 (0.39)
2001 29,380 8,657 (29.5) 899 (10.4) 114 (0.39)
2002 28,707 9,515 (33.1) 1,009 (10.6) 178 (0.62)
2003 27,905 10,254 (36.7) 1,107 (10.8) 147 (0.53)
2004 27,130 9,124 (33.6) 1,278 (14.0) 192 (0.71)
2005 26,300 9,405 (35.8) 1,336 (14.2) 198 (0.75)
2006 25,488 9,602 (37.7) 1,323 (13.8) 169 (0.66)
2007 24,732 9,146 (37.0) 1,241 (13.6) 131 (0.53)
2008 23,915 6,281 (26.3) 1,304 (20.8) 83 (0.35)
2009 23,201 6,436 (27.7) 1,399 (21.7) 83 (0.36)
2010 22,373 6,411 (28.7) 1,345 (21.0) 70 (0.31)
2011 21,613 4,531 (21.0) 1,007 (22.2) 52 (0.24)
2012 20,763 2,623 (12.6) 596 (22.7) 59 (0.28)
* Total serum PSA 4.0 ng/ml or greater, or total serum PSA 3.0 to 3.99 ng/ml and free-to
PSA tests.to 1999 approximately 10% of the respondents
reported previous PSA testing.16
In an ideal randomized trial all men in the SA but
none in the CA were screened, which would yield a
perfect estimate of the screening effect.17 In reality
some men in the SA are noncompliers (ie do not
participate) and some in the CA undergo non-
organized screening. Both situations are violationsand trial arm
Control Arm
No. Pts
No. at Least 1
PSA Test (%)
No. Pos
Test (%)* No. T1c (%)
12,342 241 (2.0) 45 (18.7) 3 (0.02)
23,187 471 (2.0) 126 (26.8) 14 (0.06)
35,276 1,049 (3.0) 227 (21.6) 38 (0.11)
47,067 2,539 (5.4) 515 (20.3) 65 (0.14)
46,173 3,492 (7.6) 708 (20.3) 83 (0.18)
45,293 5,994 (13.2) 1,071 (17.9) 79 (0.17)
44,346 7,576 (17.1) 1,348 (17.8) 121 (0.27)
43,270 9,861 (22.8) 1,777 (18.0) 144 (0.33)
42,161 10,676 (25.3) 2,177 (20.4) 194 (0.46)
40,941 10,859 (26.5) 2,222 (20.5) 242 (0.59)
39,625 11,011 (27.8) 2,147 (19.5) 182 (0.46)
38,427 9,616 (25.0) 2,106 (21.9) 151 (0.39)
37,251 10,260 (27.5) 2,237 (21.8) 150 (0.40)
36,143 10,542 (29.2) 2,434 (23.1) 173 (0.48)
34,865 10,491 (30.1) 2,317 (22.1) 159 (0.46)
33,540 7,283 (21.7) 1,629 (22.4) 152 (0.45)
32,244 4,288 (13.3) 989 (23.1) 136 (0.42)
-total PSA ratio less than 16% with incidence calculated by dividing by number of
Figure 4. Incidence of T1c prostate cancer in control and screening arms
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They can be controlled for with a counterfactual
method that builds an estimate of the screening
effect by extrapolation.18 Such a method has been
used in the ERSPC trial.19,20 Unfortunately such
methods cannot fully compensate for the intent to
treat principle, which should always be the basis of
any randomized trial.
As reported in the PLCO trial, in addition to the
high prevalence of PSA testing before randomiza-
tion, 52% of men in the CA were tested at least once
compared to 78% in the SA.11 A recent report
showed that as many as 90% of men in the CA were
tested before or during the trial.12
The Dutch section of ERSPC reported that 40% of
men in the CA were tested with PSA at least once
during the 13 years of followup.21 The Italian center
estimated that approximately 30% of participants
had been tested for PSA during the previous year in
1997 and 2001 based on interviews.16 To our
knowledge the Swedish section of ERSPC has not
published its contamination results to date.
When ERSPC was designed, contamination in the
CA was pre-estimated to be approximately
20%.19,22,23 Our results indicate that during the first
4-year period the proportion of tested men in the CA
was indeed approximately 20% but this increased
quickly. By the end of the active screeningperiod 58%of men in the CA had undergone PSA testing at least
once. The high T1c incidence of 5% in the CA reflects
this test frequency. In comparison, the risk of any
PCa in Finland by age 75 years is approximately
10%.24 During the trial no national guidelines rec-
ommended PSA testing in asymptomatic men.
Our results highlight the challenge of a popula-
tion based cancer screening trial. The setting
changes from “to screen or not to screen” to “to
screen in an organized or in an opportunistic
fashion.”11,25,26 Thus, the results of a highly
contaminated trial do not answer the original
dichotomy but rather the new quantitative com-
parison of whether it is enough to screen opportu-
nistically or whether organized screening is more
beneficial. Consequently the conclusion from a
highly contaminated trial reporting no substantial
mortality benefit such as PLCO cannot be that no
screening is as good as organized screening because
there is no group representing no screening.
This study has 2 major limitations. 1) We have no
information on PSA testing in the private clinics.
For instance, of the 2,180 men in the CA who were
diagnosed with T1c cancer 424 (19.4%) had no PSA
test findings available in our laboratory data, likely
indicating PSA testing in the private sector. Thus,
the true proportion of men with at least 1 PSA test
in the CA could possibly be up to 20% higher. 2) We
56 ESTIMATE OF OPPORTUNISTIC PROSTATE SPECIFIC ANTIGEN TESTINGhave no information on whether PSA tests were
used for screening asymptomatic men (true
contamination) or for diagnostic purposes in pa-
tients with prostate related symptoms. The latter is
likely to be frequent as the proportion of elevated
PSA results was clearly higher in the CA and it
increased as men grew older. At the Dutch center
50% of opportunistic PSA testing was true contam-
ination and 50% was diagnostic testing.21
Using the overall PSA test frequency as an indi-
cator of opportunistic screening overestimates its
frequency because true contamination cannot be
extracted from all contamination to perform revised
mortality estimates. If we extrapolate the missing
data from the private clinics (a 1.2-fold increase in
PSA tests) and consider that approximately 50% of
PSA testing represents true contamination, wecould estimate that by 4, 8 and 12 years of followup
11%, 29% and 38% of men in the CA, respectively,
had been tested with PSA at least once. Further-
more, we have no information on the extent of
diagnostic testing (ie biopsy) following the PSA test
(effective contamination).CONCLUSIONS
PSA testing frequency in the CA was initially low
but it became higher as 18% of men in the CA were
tested at least once by 4 years, 48% at 8 years and
63% at 12 years. The relative mortality reduction in
the screening arm has been less pronounced in the
Finnish trial than at the Swedish and Dutch
ERSPC centers. Contamination in the CA is likely a
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Two multicenter trials have investigated the effec- important health policy question. Compared to no
tiveness of PSA testing on prostate cancer mortal-
ity. PLCO was performed in the United States,
where PSA testing was widespread, with a 99%
intervention rate and an 86% control rate, thus,
comparing organized to opportunistic testing.1 This
small absolute difference in PSA use lowered study
power to detect the postulated expected mortality
reduction between the arms.1 In contrast, ERSPC
was done in 8 European countries, where PSA
testing was initially rare, and it showed significant
benefit.2 However, exposure to PSA also increased
in Europe with time.
Kilpel€ainen et al report 63% PSA contamination
at 12 years in the control arm of ERSPC Finland. As
with PLCO, contamination diluted differences in
deaths between study arms. This raises anscreening, organized PSA testing can effectively
reduce prostate cancer mortality but increase the
number of cancers detected. The effect of opportu-
nistic PSA testing appears to be more heteroge-
neous as it often follows no protocol. In the worst
case there is little if any effect on mortality but it
merely results in over diagnosis.3
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Randomized cancer screening trials tend to asymptomatic men (differential diagnostics vs
concentrate on the screening arm because the
information is readily available on those who are
screened. However, the relative difference between
the trial arms (eg in incidence and mortality)
appears to be more dependent on the event rate in
the control arm. Opportunistic PSA testing has
become widespread but the pace and extent of such
testing vary among populations. Furthermore, it is
not only testing but also the rigor of the diagnostic
followup procedures that ultimately affects inci-
dence and mortality.
To date testing in the control arms of various
trials has been reported incompletely, rarely
distinguishing testing among symptomatic vsscreening). Inference on the impact of opportunistic
screening has mainly been based on circumstantial
data on testing frequency in the control arm but
no solid evidence based on indications for testing.
We are looking at the shadows of these trials much
like the men tied to chairs in Plato’s Allegory of
the Cave.
Thus, the mortality impact, if any, of current
opportunistic PSA testing remains unclear. A
quarter of a century ago PSA testing was uncom-
mon and the benefits of organized screening could
be demonstrated when screening na€ıve populations.
Now we can only compare different frequencies and
intensities of screening.
